US Biotechnology One Interesting Nugget from Each Team in the Last Week & Looking Ahead

Research evidence excerpt

US Biotechnology One Interesting Nugget from Each Team in the Last Week & Looking Ahead

J P M O R G A N North America Equity Research

15 May 2026

US Biotechnology

One Interesting Nugget from Each Team in the Last

Week & Looking Ahead

The J.P. Morgan Biotech Team

Jessica Fye AC

(1-212) 622-4165

jessica.m.fye@jpmorgan.com

Anupam Rama AC

We wanted to provide one interesting nugget from each team’s coverage universe (1-212) 622-0900

anupam.rama@jpmorgan.com

from the last week as well as highlight upcoming calls and prior conference call

Tessa T Romero ACreplays. Please see below.

(1-212) 622-4484

tessa.t.romero@jpmchase.com

One interesting nugget from each team’s coverage universe in the last week AC Brian Cheng

• Solid Bio (SLDB – Rama): Yes, timelines have shifted somewhat for SGT-003 (1-212)brian.cheng@jpmorgan.com622-0449

in DMD; however, we believe this will ultimately prove to be a prudent J.P. Morgan Securities LLC

decision by the company. Indeed, Solid will continue to meet with the Agency

into the fall (multiple meetings are anticipated related to INSPIRE statistical

plan and also the regulatory pathway). With the debate on what is needed for

an accelerated approval pathway in the disease in the US, in our view, having

the most robust data in hand will be helpful (micro-dystrophin expression,

functional data, and safety data base). With a very clean safety profile to date

(no ALIs or myocarditis – which have been observed with competitors; n=47

patients dosed), we do see AA as very much on the table for SGT-003.

• Agios Pharmaceuticals (AGIO – Romero): Earlier this week, Agios

announced that the supplemental new drug application (sNDA) for mitapivat

in sickle cell disease (SCD) has now been submitted to the FDA for accelerated